Rafivirumab
Based on 1 Customer Validation
Rafivirumab (CR57) is an anti-rabies virus monoclonal antibody for the prophylaxis of rabies. Rafivirumab has neutralizing potency against a broad spectrum of RABV variants. Rafivirumab can be used for research of cocktails.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 95.00%
- No. CAS: 944548-37-2
- Peso molecular:145.76 kDa
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Actividad biológica
Human IgG1 lambda2
Virus
Rabies virus GP
Rafivirumab shows neutralization effect against series of RABV isolates[2].
Rafivirumab binds to antigenic site I of the RABV glycoprotein[3].
Rafivirumab fully neutralizs the wild type ERA439 and N336D R346K with EC50 ranging between 3 and 5 pg/mL[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Syrian hamsters infected with bat rabies viruses[2].
-
Dosage:6, 12, 16, 18 or 24 μg/kg of CL184 (mixture of Rafivirumab and CR4098 in 1:1 protein ratio)
-
Administration:i.m.
-
Result:Increased survival rate.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 lambda2
ELISA, FACS, Functional assay
Chemical Information
-
No. CAS 944548-37-2
-
Appearance Liquid
-
Peso molecular 145.76 kDa
-
Color Colorless to light yellow
-
SMILES
[Rafivirumab]
-
Synonyms
CR57
-
Envío
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
-
Ficha de datos (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Referencias
[1]. Kramer RA, et al. The human antibody repertoire specific for rabies virus glycoprotein as selected from immune libraries. Eur J Immunol. 2005 Jul;35(7):2131-45. [Content Brief]
[2]. Franka R, et al. In Vivo Efficacy of a Cocktail of Human Monoclonal Antibodies (CL184) Against Diverse North American Bat Rabies Virus Variants. Trop Med Infect Dis. 2017 Sep 20;2(3):48. [Content Brief]
[3]. Ejemel M, et al. A cocktail of human monoclonal antibodies broadly neutralizes North American rabies virus variants as a promising candidate for rabies post-exposure prophylaxis. Sci Rep. 2022 Jun 7;12(1):9403. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Rafivirumab Related Classifications
HY-P99811 Related Classifications
Powered by Bioz